Home
About Sunhawk Vision Biotech
Company Profile
Awards
Board of Directors
Executive Team
Milestone and History
News
Research and Development
Technology Platform
Patents
Product Pipeline
Projects
Investor Relations
Financial Information
Corporate Governance
Board of Directors
Functional Committee
Major Internal Policies
Stakeholder Communication
ESG-Sustainability
Other Important Information Related to Corporate Governance
Shareholder Services
Material Information
Contact
繁中
Menu
Menu
Enrollment of phase-2 myopia control trial (NCT06579287) of Sunhawk vision had successfully completed on December 31, 2025.
2025.12.31
分享
分享至 X
Share on Facebook
Share on WhatsApp
Share on Pinterest
Share by Mail
Scroll to top
